tofacitinib and Autoimmune-Lymphoproliferative-Syndrome

tofacitinib has been researched along with Autoimmune-Lymphoproliferative-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for tofacitinib and Autoimmune-Lymphoproliferative-Syndrome

ArticleYear
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
    Journal of clinical immunology, 2015, Volume: 35, Issue:7

    Autoimmune lymphoproliferative syndrome (ALPS) is a non-malignant genetic disorder of lymphocyte homeostasis with defective Fas-mediated apoptosis. Current therapies for ALPS primarily target autoimmune manifestations with non-specific immune suppressants with variable success thus highlighting the need for better therapeutics for this disorder.. The spectrum of clinical manifestations of ALPS is mirrored by MRL/lpr mice that carry a loss of function mutation in the Fas gene and have proven to be a valuable model in predicting the efficacy of several therapeutics that are front-line modalities for the treatment of ALPS. We evaluated the potential efficacy of tofacitinib, an orally active, pan-JAK inhibitor currently approved for rheumatoid arthritis as a single agent modality against ALPS using MRL/lpr mice.. We demonstrate that a 42-day course of tofacitinib therapy leads to a lasting reversal of lymphadenopathy and autoimmune manifestations in the treated MRL/lpr mice, Specifically, in treated mice the peripheral blood white blood cell counts were reversed to near normal levels with almost a 50 % reduction in the TCRαβ(+)CD4(-)CD8(-)T lymphocyte numbers that coincided with a parallel increase in CD8(+) T cells without a demonstrable effect on CD4(+) lymphocytes including FoxP3(+) regulatory T cells. The elevated plasma IgG and IgA levels were also drastically lowered along with a significant reduction in plasmablasts and plasmacytes in the spleen.. On the basis of these results, it is likely that tofacitinib would prove to be a potent single agent therapeutic modality capable of ameliorating both offending lymphadenopathy as well as autoimmunity in ALPS patients.

    Topics: Animals; Autoimmune Lymphoproliferative Syndrome; Disease Models, Animal; fas Receptor; Humans; Immunoglobulins; Janus Kinase 3; Mice; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2015